Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Abbott AxSYM Vancomycin II assay: multicenter evaluation and interference studies

H M Azzazy1, P P Chou, J H Tsushima

  • 1Department of Pathology, University of Maryland School of Medicine, Baltimore, USA.

Therapeutic Drug Monitoring
|April 29, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Performance characteristics of a new myoglobin microparticle enzyme immunoassay: a multicenter evaluation.

Clinical biochemistry·2000
Same author

An extralemniscal component of the mustached bat inferior colliculus selective for direction and rate of linear frequency modulations.

The Journal of comparative neurology·2000
Same author

College students and the diagnosis of attention deficit hyperactivity disorder.

Journal of American college health : J of ACH·2000
Same author

Problems of an aging population in an era of technology.

Journal (Canadian Dental Association)·2000
Same author

Function of RRM domains of Drosophila melanogaster ELAV: Rnp1 mutations and rrm domain replacements with ELAV family proteins and SXL.

Genetics·2000
Same author

The UNC-119 family of neural proteins is functionally conserved between humans, Drosophila and C. elegans.

Journal of neurogenetics·2000
Same journal

Mass Spectrometric Characterization of Flucloxacillin Binding to Serum Albumin in Hospitalized Patients With Hypoalbuminemia: An Observational Pilot Study.

Therapeutic drug monitoring·2026
Same journal

Therapeutic Drug Monitoring-Driven Prediction of Cyclosporine-Associated Liver Injury in Pediatric Thalassemia After Hematopoietic Stem Cell Transplantation.

Therapeutic drug monitoring·2026
Same journal

Donor-derived Cell-free DNA Does Not Improve the Detection of Acute Kidney Allograft Rejection Beyond Urinary CXCL9 and CXCL10.

Therapeutic drug monitoring·2026
Same journal

A Novel Dosing Strategy for Tacrolimus in Lung Transplant Recipients: Integrating Machine Learning with Population Pharmacokinetic Analysis.

Therapeutic drug monitoring·2026
Same journal

Recommendations for Assessing Methodological Quality in Systematic Reviews of Population Pharmacokinetic Models: A Systematic Review.

Therapeutic drug monitoring·2026
Same journal

Wide-Range Quantification of Belumosudil in Patients with Chronic Graft-Versus-Host Disease by High-Performance Liquid Chromatography.

Therapeutic drug monitoring·2026
See all related articles

The Abbott AxSYM Vancomycin II immunoassay accurately measures vancomycin levels in patients, including those with renal dysfunction. This method shows good agreement with existing techniques and is unaffected by common interferences.

Area of Science:

  • Clinical Chemistry
  • Immunodiagnostics
  • Pharmacokinetics

Background:

  • Accurate vancomycin monitoring is crucial for therapeutic efficacy and minimizing toxicity.
  • Evaluating new diagnostic assays is essential for improving patient care.

Purpose of the Study:

  • To assess the performance characteristics of the Abbott AxSYM Vancomycin II immunoassay.
  • To compare the AxSYM Vancomycin II assay with established methods for vancomycin measurement.

Main Methods:

  • The Abbott AxSYM Vancomycin II immunoassay was evaluated using patient sera.
  • Performance was assessed by correlation analysis with Abbott AxSYM Vancomycin, Abbott TDx/TDxFLx, Syva EMIT, DuPont ACA, and HPLC methods.
  • Interference from human antimouse antibody (HAMA) and vancomycin crystalline degradation product (CDP) was investigated.

Related Experiment Videos

Main Results:

  • The AxSYM Vancomycin II assay demonstrated acceptable correlation with multiple reference methods (slope >0.95, r >0.97).
  • Satisfactory agreement was observed in patients with and without renal dysfunction.
  • No significant interference was detected from HAMA or vancomycin CDP.

Conclusions:

  • The Abbott AxSYM Vancomycin II assay is a reliable method for therapeutic drug monitoring of vancomycin.
  • The assay provides accurate results in diverse patient populations, including those with impaired renal function.